- Home
- VNOM vs MIRM Comparison
VNOM vs MIRM Comparison
Compare VNOM & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VNOM | MIRM |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.2B |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VNOM | MIRM |
|---|---|---|
| Price | $45.31 | $113.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | $54.85 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 1.6M | 734.0K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $1,395,000,000.00 | $19,138,000.00 |
| Revenue This Year | $69.89 | $26.22 |
| Revenue Next Year | N/A | $22.04 |
| P/E Ratio | $85.23 | ★ N/A |
| Revenue Growth | ★ 62.02 | N/A |
| 52 Week Low | $35.10 | $50.25 |
| 52 Week High | $51.13 | $130.00 |
Technical Indicators
Market Signals| Indicator | VNOM | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 64.66 | 45.23 |
| Support Level | $44.38 | $87.93 |
| Resistance Level | $47.83 | $114.99 |
| Average True Range (ATR) | 0.88 | 5.04 |
| MACD | 0.52 | -1.91 |
| Stochastic Oscillator | 97.89 | 10.70 |
Price Performance
Historical ComparisonAbout VNOM Viper Energy Inc.
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.